Eribulin

Generic Name: Eribulin

Brand Names: Halaven, Eribulin Baxter, Mevlyq

Drug Type: Small Molecule

Chemical Formula: C_₄₀H_₅₉NO_₁₁

CAS Number: 253128-41-5

Unique Ingredient Identifier: LR24G6354G

Background: Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for use in the treatment of advanced solid tumors .

Indication: For the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic cancer.

Associated Conditions: Metastatic Liposarcoma, Refractory, metastatic Breast cancer, Unresectable Liposarcoma

Clinical Trials

Zanzalintinib Combined With Eribulin in Advanced Liposarcoma and Leiomyosarcoma

Phase 1

Not yet recruiting

Conditions: Advanced Leiomyosarcoma
Adipocytic Sarcoma
Advanced Liposarcoma

Interventions: Drug: Zanzalintinib
Drug: Eribulin

First Posted Date: 2025-05-04

Last Posted Date: 2025-05-04

Lead Sponsor: Washington University School of Medicine

Target Recruit Count: 18

Registration Number: NCT06957431

Locations: 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States

Study of JSKN016 Combination Therapy in Inoperable Locally Advanced or Metastatic HER2-Negative Breast Cancer

Phase 1

Not yet recruiting

Conditions: Inoperable Locally Advanced HER2-Negative Breast Cancer
Metastatic HER2-Negative Breast Cancer

Interventions: Drug: JSKN016
Drug: Paclitaxel (albumin bound)
Drug: Eribulin
Drug: Capecitabine
Drug: Pembrolizumab

First Posted Date: 2025-04-24

Last Posted Date: 2025-04-30

Lead Sponsor: Jiangsu Alphamab Biopharmaceuticals Co., Ltd

Target Recruit Count: 180

Registration Number: NCT06942234

JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC

Phase 2

Not yet recruiting

Conditions: Triple Negative Breast Cancer (TNBC)
Metastatic Breast Cancer

Interventions: Drug: Ivarmacitinib
Drug: Camrelizumab (SHR-1210)
Drug: Eribulin

First Posted Date: 2024-12-12

Last Posted Date: 2024-12-12

Lead Sponsor: Fudan University

Target Recruit Count: 40

Registration Number: NCT06731153

Locations: 🇨🇳
Breast cancer institute of Fudan University Cancer Hospital, Shanghai, Shanghai, China

Testing the Addition of an Investigational Anti-Cancer Drug, ASTX660 (Tolinapant), to a Usual Chemotherapy Treatment (Eribulin) for Treatment of Advanced Triple Negative Breast Cancer

Phase 1

Suspended

Conditions: Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Invasive Breast Carcinoma
Locally Advanced HER2-Negative Breast Carcinoma
Locally Advanced Hormone Receptor-Positive Breast Carcinoma
Locally Advanced Triple-Negative Breast Carcinoma
Metastatic HER2-Negative Breast Carcinoma
Metastatic Hormone Receptor-Positive Breast Carcinoma
Metastatic Triple-Negative Breast Carcinoma
Unresectable HER2-Negative Breast Carcinoma

Interventions: Procedure: Biopsy Procedure
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Drug: Eribulin Mesylate
Procedure: Magnetic Resonance Imaging
Drug: Tolinapant
Procedure: X-Ray Imaging

First Posted Date: 2024-09-19

Last Posted Date: 2025-04-22

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 42

Registration Number: NCT06590558

Locations: 🇺🇸
University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
🇺🇸
Ohio State University Comprehensive Cancer Center LAO, Columbus, Ohio, United States
🇺🇸
Huntsman Cancer Institute/University of Utah, Salt Lake City, Utah, United States

Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer

Phase 2

Not yet recruiting

Conditions: Neoplasm Metastasis
Bevacizumab
Breast Neoplasms
Drug Therapy

Interventions: Drug: Eribulin
Drug: Bevacizumab

First Posted Date: 2024-08-06

Last Posted Date: 2024-08-06

Lead Sponsor: Wang Jiayu

Target Recruit Count: 60

Registration Number: NCT06539559

Locations: 🇨🇳
Beijing Chaoyang District San Huan Cancer Hospital, Beijing, Beijing, China
🇨🇳
Cancer Hospital of HuanXing ChaoYang District, Beijing, Beijing, China
🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China

FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer

Phase 3

Not yet recruiting

Conditions: Triple Negative Breast Cancer

Interventions: Drug: FDA018-ADC
Drug: Eribulin
Drug: Capecitabine
Drug: Gemcitabine
Drug: Vinorelbine

First Posted Date: 2024-07-25

Last Posted Date: 2024-07-25

Lead Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.

Target Recruit Count: 350

Registration Number: NCT06519370

Locations: 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

Phase 2

Recruiting

Conditions: Locally Advanced Breast Cancer
Triple Negative Breast Cancer
Metastatic Triple Negative Breast Cancers

Interventions: Drug: BNT327 Dose Level 1 (DL1)
Drug: BNT327 Dose Level 1 (DL2)
Drug: Paclitaxel
Drug: Carboplatin
Drug: Eribulin
Drug: Nab-placlitaxel
Drug: BNT327 Optimized Dose
Drug: Gemcitabine
Drug: BNT327 Equivalent Q3W Dose

First Posted Date: 2024-06-07

Last Posted Date: 2025-05-02

Lead Sponsor: BioNTech SE

Target Recruit Count: 70

Registration Number: NCT06449222

Locations: 🇹🇷
Gazi University Medical Faculty, Yenimahalle, Turkey
🇺🇸
Stanford University School of Medicine - Stanford Cancer Institute (SCI) - Stanford Women's Cancer Center, Palo Alto, California, United States
🇺🇸
Rutgers Cancer Institute of NJ (Rutgers, The State University of New Jersey), New Brunswick, New Jersey, United States

and more 63 locations

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer

Phase 3

Recruiting

Conditions: Metastatic HER2-positive Breast Cancer

Interventions: Drug: Trastuzumab
Drug: Zanidatamab
Drug: Eribulin
Drug: Vinorelbine
Drug: Gemcitabine
Drug: Capecitabine

First Posted Date: 2024-05-30

Last Posted Date: 2025-05-21

Lead Sponsor: Jazz Pharmaceuticals

Target Recruit Count: 550

Registration Number: NCT06435429

Locations: 🇨🇦
The Ottawa Hospital Cancer Centre, Ottawa, Canada
🇺🇸
Arizona Oncology Tucson - Wilmot, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center, Tucson, Arizona, United States

and more 114 locations